#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Mastocytosis Cardiac failure acute Extra-osseous Ewing's sarcoma Frontotemporal dementia Soft tissue necrosis Hepatocellular carcinoma Acute lymphocytic leukaemia Transitional cell cancer of the renal pelvis and ureter Fibrodysplasia ossificans progressiva Cholestatic pruritus Epileptic encephalopathy Renal cell carcinoma Hodgkin's disease Cortical dysplasia Factor VIII deficiency More trials…

    Learn about Rare Diseases

    Hereditary optic atrophy – Basic Information Glycogen storage disease type I – Life with Disease Hairy cell leukaemia – Trials in Disease Wolfram syndrome – Life with Disease Ornithine transcarbamoylase deficiency – Treatment Cystic fibrosis – Treatment Undifferentiated sarcoma – Diagnostics Focal segmental glomerulosclerosis – Trials in Disease Short-bowel syndrome – Life with Disease Cholangitis sclerosing – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ferric Carboxymaltose Bi 764532 ALE.P03 Transpocart19 HYDROGEN Isaralgagene Civaparvovec Ads-010 Gen1053 Myrrh Acalabrutinib Levodropropizine Ifosfamide Namodenoson Df1001 Lecanemab Fluticasone Furoate Csm-Gw Linagliptin Isatuximab Vb10.16 More therapies…

    Learn about Your Condition

    Muscle hypertrophy Retinopathy of prematurity Dermatitis atopic Staphylococcal infection Peritoneal abscess Oxygen saturation Acute cardiac event Soft tissue sarcoma Optic ischaemic neuropathy Pancreatitis relapsing Benign renal neoplasm Spinal cord injury cervical Hypochondroplasia Endocarditis enterococcal Colon cancer stage II More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Long‑Term Safety and Efficacy Study of ENTR‑601‑45 and ENTR‑601‑44 in Participants with Duchenne Muscular Dystrophy

    Recruiting

    2 1 1
    Belgium Italy The Netherlands Spain

  • Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Nemolizumab
    Bulgaria Croatia France Greece Italy Poland +1

  • Phase I/II Study of AZD6621 Safety and Efficacy in Adult Men with Metastatic Prostate Cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    Belgium Italy The Netherlands Poland Spain

  • A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

    Recruiting

    3 1
    Investigated Diseases:
    • Non-small cell lung cancer stage I
    Investigated Drugs:
    • Mrna-4157
    • Pembrolizumab
    France Germany Greece Hungary Italy The Netherlands +2

  • Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

    Recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • SPY002
    Austria Belgium Bulgaria Croatia Czechia France +9

  • Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastric cancer
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Azd0901
    • Zolbetuximab
    • Rilvegostomig
    Belgium France Germany Hungary Italy The Netherlands +2
Previous Page
1 … 3 4 5 6 7 … 1,645
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!